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Backkground: Hemophagocytic lymphohistiocytosis (HLH)
is a life-threatening condition characterized by prolonged
fever, hepatosplenomegaly, cytopenia, and hemophagocy-
tosis. Primary HLH is considered fatal unless treated by
hematopoietic stem cell transplantation (HSCT).
Method: Herein we report six Iranian patients as a case
series with primary HLH and their outcome from a single
tertiary-care center Between 2000-2012.
Results: Griscelli syndrome type 2 (GS2) was diagnosed in 3
patients based on clinical, laboratory, and microscopic
features of partial albinism and ﬁnding of RAB27Amutations
in 2 patients tested. Two patients were on the HLH-2004
continuation therapy and waiting for HSCT, but no matched
donor yet: The ﬁrst case is in 2nd remission after 1.5 years;
he had history of relapse in maintenance phase of HLH-2004
protocol which more immunosuppressive treatment was
advised. The second case is in remission after 1 year. Two
other patients died, while waiting for a suitable donor: case 3
had history of recurrent HLH and died after 6 months; and
the case 4 had history of progression to T-cell ALL after 2
years and dead due to relapse of ALL, sepsis and DIC despite
chemotherapy after 3 years. Two patients underwent HSCT;
patient 5 had a HLA-identical sibling donor and patient 6 had
a cord blood-, unrelated, one antigen mismatched donor.
Both patients were treated according to the HLH-2004
treatment protocol and none had active disease at the time of
HSCT. Patient 5 who were diagnosed with GS2 responded
well and remained in remission through 24 months of
follow-up, while another case died because of graft-versus-
host disease and infection on day 136 after HSCT.
Conclusion: HSCT seems to be the only curative treatment
for primary HLH which drastically improve survival of the
patients. Making a deﬁnite diagnosis conﬁrmed by gene
mutation studies is helpful to provide genetic counseling and
prenatal diagnosis and, more important, dictate the need for
HSCT later in the patient's course.
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Aim: Following Hematopoietic stem cell transplantation
(HSCT), the accurate monitoring of donor-derived cells
prospectively is critical for understanding sustained
engraftment or whether therapeutic intervention is needed,
in turn predicting the success or failure of HSCT.We designed
a highly sensitive, quantitative PCR (qPCR) research assay
speciﬁcally for engraftment monitoring following HSCT in
a research setting. It can accurately detect recipient cells up
to 0.01% while also reducing workﬂow and analysis burdens
as compared to routine STR testings. To enable broader
access to the AlleleSEQR qPCR Chimerism Assay RUO across
more clinical research laboratories, we have assessed
performance of the multiplexed screening assay across ﬁve
different qPCR platforms from four manufacturers.Method: A panel of 34 qPCR research assays to bi-allelic
indels across the genome enables informative marker iden-
tiﬁcation and quantiﬁcation to occur within a few hours and
without the need for capillary electrophoresis. To decrease
our current sample volume requirements, increase
throughput and enable multiple donor screening scenarios
across multiple transplantation centers, we evaluated
a multiplexed assay approach for marker identiﬁcation
utilizing ﬁve different qPCR platforms. The alleles are scored
in relation to ampliﬁcation of an endogenous control assay
and 6-8 samples can be evaluated simultaneously across all
platforms.
Results: Multiplexing the assays to 2-4 assays/well yielded
identical results when compared to single well 34 assays. In
addition, using ﬁve different qPCR platforms i.e. Applied
Biosystems 7500 and ViiA7 Real-Time PCR System, Qiagen
Rotor-Gene Q, Focus 3M Integrated Cycler and Roche
LightCycler 480 System, the described multiplexed qPCR
approach yielded results with 100% concordance in identi-
fying informative markers on six unique Coriell DNA across
platforms.
Conclusions: The results from this multiplexed qPCR
research system for screening of informative markers were
100% concordant to results generated when using the assays
individually. Performance of the multiplex qPCR assays were
independent of the platform providing supportive results for
possible future use in transplant centers.397
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Introduction: Patients with acute myelogenous leukemia
(AML) or non responsive myelodysplastic syndrome (MDS)
who fail to achieve a complete remission, have unfavorable
cytogenetics or are refractory to therapy have a poor prog-
nosis. Allogeneic HSCT is frequently considered a salvage
option for these patients although remissions are short-lived.
New strategies are needed for maintaining remission in this
extremely high risk patient group. We hypothesized hypo-
methylating agents post allogeneic HSCT would enable
patients to remain in complete remission.
Methods: Eleven patients were treated. Patient characteris-
tics: median age, 48 years (range, 18-70 years), PBSC (n¼9) or
bone marrow (n¼2); Diagnoses AML¼ 10, Non- responsive
MDS¼1, CIBMTR disease risk category: High [n¼8], Inter-
mediate [n¼1], Low [n¼2]; 36% of the patients had primary
induction failure, 54% had complex molecular abnormalities
with 18% of the patients having deletion 11q 23 molecular
abnormalities. Donors were unrelated (36%) and related
(64%). All but 1 donor-recipient pairs were fully matched.
Preparative regimen- busulfan based (16mg/kg or equiva-
lent) (82%), TBI  12 Gy (9%) based or reduced-intensity
haplo-identical regimen (9%). The median number of prior
chemotherapy regimens was 2.5 (range, 2-6). Azacitidine
(n¼10) or decitabine (n¼1) was selected at physician
discretion as a planned prophylactic regimen post allogeneic
HSCT engraftment. Initial starting doses were based on
hematological conditions at the time of therapy initiation.
Results: Ten patients received azacitidine subcutaneously
daily for seven days for a median of 5 cycles (range, 1-10
